Treatment  ||| S:0 E:10 ||| NN
and  ||| S:10 E:14 ||| CC
prevention  ||| S:14 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
aortic  ||| S:28 E:35 ||| JJ
regurgitation  ||| S:35 E:49 ||| NN
after  ||| S:49 E:55 ||| IN
transcatheter  ||| S:55 E:69 ||| FW
aortic  ||| S:69 E:76 ||| FW
valve  ||| S:76 E:82 ||| FW
implantation  ||| S:82 E:95 ||| FW
Significant  ||| S:95 E:107 ||| FW
aortic  ||| S:107 E:114 ||| FW
regurgitation  ||| S:114 E:128 ||| FW
( ||| S:128 E:129 ||| -LRB-
AR ||| S:129 E:131 ||| NNP
)  ||| S:131 E:133 ||| -RRB-
after  ||| S:133 E:139 ||| IN
transcatheter  ||| S:139 E:153 ||| FW
aortic  ||| S:153 E:160 ||| FW
valve  ||| S:160 E:166 ||| FW
implantation  ||| S:166 E:179 ||| FW
( ||| S:179 E:180 ||| -LRB-
TAVI ||| S:180 E:184 ||| NNP
)  ||| S:184 E:186 ||| -RRB-
has  ||| S:186 E:190 ||| VBZ
been  ||| S:190 E:195 ||| VBN
shown  ||| S:195 E:201 ||| VBN
to  ||| S:201 E:204 ||| TO
be  ||| S:204 E:207 ||| VB
associated  ||| S:207 E:218 ||| VBN
with  ||| S:218 E:223 ||| IN
worse  ||| S:223 E:229 ||| JJR
mid-term  ||| S:229 E:238 ||| JJ
outcome ||| S:238 E:245 ||| NN
.  ||| S:245 E:247 ||| .
The  ||| S:247 E:251 ||| DT
two-year  ||| S:251 E:260 ||| JJ
follow-up  ||| S:260 E:270 ||| JJ
results  ||| S:270 E:278 ||| NNS
of  ||| S:278 E:281 ||| IN
the  ||| S:281 E:285 ||| DT
PARTNER  ||| S:285 E:293 ||| NNP
US  ||| S:293 E:296 ||| NNP
trial  ||| S:296 E:302 ||| NN
showed  ||| S:302 E:309 ||| VBD
that  ||| S:309 E:314 ||| IN
not  ||| S:314 E:318 ||| RB
only  ||| S:318 E:323 ||| RB
â‰¥3 ||| S:323 E:325 ||| CD
/ ||| S:325 E:326 ||| CD
4  ||| S:326 E:328 ||| CD
AR  ||| S:328 E:331 ||| JJ
grade ||| S:331 E:336 ||| NN
,  ||| S:336 E:338 ||| ,
but  ||| S:338 E:342 ||| CC
also  ||| S:342 E:347 ||| RB
grade  ||| S:347 E:353 ||| CD
2  ||| S:353 E:355 ||| CD
had  ||| S:355 E:359 ||| VBD
a  ||| S:359 E:361 ||| DT
significant  ||| S:361 E:373 ||| JJ
impact  ||| S:373 E:380 ||| NN
on  ||| S:380 E:383 ||| IN
mortality ||| S:383 E:392 ||| NN
.  ||| S:392 E:394 ||| .
Thus ||| S:394 E:398 ||| RB
,  ||| S:398 E:400 ||| ,
prevention  ||| S:400 E:411 ||| NN
and  ||| S:411 E:415 ||| CC
treatment  ||| S:415 E:425 ||| NN
of  ||| S:425 E:428 ||| IN
significant  ||| S:428 E:440 ||| JJ
AR  ||| S:440 E:443 ||| NN
after  ||| S:443 E:449 ||| IN
TAVI  ||| S:449 E:454 ||| NNP
is  ||| S:454 E:457 ||| VBZ
of  ||| S:457 E:460 ||| IN
great  ||| S:460 E:466 ||| JJ
importance ||| S:466 E:476 ||| NN
.  ||| S:476 E:478 ||| .
Usually ||| S:478 E:485 ||| RB
,  ||| S:485 E:487 ||| ,
AR  ||| S:487 E:490 ||| NNP
after  ||| S:490 E:496 ||| IN
TAVI  ||| S:496 E:501 ||| NNP
consists  ||| S:501 E:510 ||| VBZ
mostly  ||| S:510 E:517 ||| RB
of  ||| S:517 E:520 ||| IN
paravalvular  ||| S:520 E:533 ||| JJ
leak  ||| S:533 E:538 ||| NN
and  ||| S:538 E:542 ||| CC
significant  ||| S:542 E:554 ||| JJ
central  ||| S:554 E:562 ||| JJ
AR  ||| S:562 E:565 ||| NNP
is  ||| S:565 E:568 ||| VBZ
uncommon ||| S:568 E:576 ||| JJ
.  ||| S:576 E:578 ||| .
Here  ||| S:578 E:583 ||| RB
we  ||| S:583 E:586 ||| PRP
describe  ||| S:586 E:595 ||| VBP
measures  ||| S:595 E:604 ||| NNS
to  ||| S:604 E:607 ||| TO
decrease  ||| S:607 E:616 ||| VB
the  ||| S:616 E:620 ||| DT
risk  ||| S:620 E:625 ||| NN
of  ||| S:625 E:628 ||| IN
AR  ||| S:628 E:631 ||| NNP
after  ||| S:631 E:637 ||| IN
TAVI  ||| S:637 E:642 ||| NNP
which  ||| S:642 E:648 ||| WDT
are  ||| S:648 E:652 ||| VBP
currently  ||| S:652 E:662 ||| RB
available ||| S:662 E:671 ||| JJ
.  ||| S:671 E:673 ||| .
